History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C
The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV. Advancements in this area have been achieved through efforts and technical breakthrou...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
UANL. Facultad de Medicina
2015
|
| Subjects: | |
| Online Access: | http://eprints.uanl.mx/11636/1/S166557961500037X_S300_en.pdf |
| _version_ | 1824413410571321344 |
|---|---|
| author | Bryan Marrugo, Owen Lloyd Ramos Jiménez, Javier Barrera Saldaña, Hugo Alberto Rojas Martínez, Augusto Vidaltamayo, Román Rivas Estilla, Ana María |
| author_facet | Bryan Marrugo, Owen Lloyd Ramos Jiménez, Javier Barrera Saldaña, Hugo Alberto Rojas Martínez, Augusto Vidaltamayo, Román Rivas Estilla, Ana María |
| author_sort | Bryan Marrugo, Owen Lloyd |
| collection | Repositorio Institucional |
| description | The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV. Advancements in this area have been achieved through
efforts and technical breakthroughs in different scientific fields. The improvement in the treatment
of HCV infection is a good example of what is needed for efficient antiviral therapy. A thorough description of the events that lead to the development of specifically targeted antiviral therapy or HCV (STAT-C) could be useful to further improve research for treating many other viral diseases in the future. Similar to HIV-1 and HBV treatment, combination therapy along with personalized medicine approaches have been necessary to successfully treat HCV patients. This review is focused on what has been done to develop a successful HCV therapy and the drawbacks along the way |
| format | Article |
| id | eprints-11636 |
| institution | UANL |
| language | English |
| publishDate | 2015 |
| publisher | UANL. Facultad de Medicina |
| record_format | eprints |
| spelling | eprints-116362024-12-09T17:47:14Z http://eprints.uanl.mx/11636/ History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C Bryan Marrugo, Owen Lloyd Ramos Jiménez, Javier Barrera Saldaña, Hugo Alberto Rojas Martínez, Augusto Vidaltamayo, Román Rivas Estilla, Ana María QD Química RC Medicina Interna, Psiquiatría, Neurología The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV. Advancements in this area have been achieved through efforts and technical breakthroughs in different scientific fields. The improvement in the treatment of HCV infection is a good example of what is needed for efficient antiviral therapy. A thorough description of the events that lead to the development of specifically targeted antiviral therapy or HCV (STAT-C) could be useful to further improve research for treating many other viral diseases in the future. Similar to HIV-1 and HBV treatment, combination therapy along with personalized medicine approaches have been necessary to successfully treat HCV patients. This review is focused on what has been done to develop a successful HCV therapy and the drawbacks along the way UANL. Facultad de Medicina 2015 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/11636/1/S166557961500037X_S300_en.pdf http://eprints.uanl.mx/11636/1.haspreviewThumbnailVersion/S166557961500037X_S300_en.pdf Bryan Marrugo, Owen Lloyd y Ramos Jiménez, Javier y Barrera Saldaña, Hugo Alberto y Rojas Martínez, Augusto y Vidaltamayo, Román y Rivas Estilla, Ana María (2015) History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Medicina universitaria, 17 (68). pp. 165-174. ISSN 1665-5796 |
| spellingShingle | QD Química RC Medicina Interna, Psiquiatría, Neurología Bryan Marrugo, Owen Lloyd Ramos Jiménez, Javier Barrera Saldaña, Hugo Alberto Rojas Martínez, Augusto Vidaltamayo, Román Rivas Estilla, Ana María History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | History and progress of antiviral drugs: from acyclovir
to direct-acting antiviral agents (DAAs) for Hepatitis C |
| title_full | History and progress of antiviral drugs: from acyclovir
to direct-acting antiviral agents (DAAs) for Hepatitis C |
| title_fullStr | History and progress of antiviral drugs: from acyclovir
to direct-acting antiviral agents (DAAs) for Hepatitis C |
| title_full_unstemmed | History and progress of antiviral drugs: from acyclovir
to direct-acting antiviral agents (DAAs) for Hepatitis C |
| title_short | History and progress of antiviral drugs: from acyclovir
to direct-acting antiviral agents (DAAs) for Hepatitis C |
| title_sort | history and progress of antiviral drugs from acyclovir to direct acting antiviral agents daas for hepatitis c |
| topic | QD Química RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/11636/1/S166557961500037X_S300_en.pdf |
| work_keys_str_mv | AT bryanmarrugoowenlloyd historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc AT ramosjimenezjavier historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc AT barrerasaldanahugoalberto historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc AT rojasmartinezaugusto historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc AT vidaltamayoroman historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc AT rivasestillaanamaria historyandprogressofantiviraldrugsfromacyclovirtodirectactingantiviralagentsdaasforhepatitisc |